WALTHAM, Mass • 2023-04-03

BostonGene Highlights Comprehensive Approach to Precision Medicine at hubXchange’s East Coast Genomics in Precision Oncology 2023

5 min to read

BostonGene announced today that it will participate and present at the hubXchange’s East Coast Genomics in Precision Oncology 2023, taking place April 5 in Boston, Massachusetts
WALTHAM, Mass, April 3, 2023

BostonGene announced today that it will participate and present at the hubXchange’s East Coast Genomics in Precision Oncology 2023, taking place April 5 in Boston, Massachusetts. The event brings together executives from pharma and biotech to address and find solutions to the key issues that currently need to be addressed in genomics-led oncology precision medicine strategies.

Presentation details:



Elucidation of the Cellular and Molecular Features of the TME Underlying Immune Escape and IO Failure

  • Wednesday, April 5 | 1:20 PM ET

  • Speaker: Alexander Bagaev, PhD, VP, Product Development, BostonGene


This session will highlight BostonGene’s comprehensive profile of a patient’s disease for therapy selection and stratification for IO clinical trials to improve outcomes by using CLIA-certified advanced whole exome and whole transcriptome sequencing paired with deep immunoprofiling and best-in-class analytics.

"I am excited to participate in the East Coast Genomics in Precision Oncology 2023 and to present how BostonGene’s transcriptional profiling and advanced analytics can reveal detailed characteristics of functional immune programs in the tumor microenvironment.,” said Alexander Bagaev, PhD, VP, Product Development at BostonGene. “Our comprehensive molecular profiling approach and innovative bioinformatics platform stratifies patients based on IO response and identifies the most effective therapy, ultimately improving patient outcomes.”

About BostonGene Corporation

BostonGene has a mission to provide transformative, AI-integrated molecular analytics and biomarker discovery for precision matching of therapies to improve the lives of patients living with cancer and other immune-related diseases. BostonGene’s service model provides customized client solutions using a multi-omic approach prioritized for real-world impact, including optimized standard-of-care therapies, accelerated research and cost-effective, measurable results. BostonGene’s tests reveal key drivers of each patient’s unique disease profile, including an in-depth profile of the immune microenvironment, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each patient. For more information, visit BostonGene at http://www.BostonGene.com.

Erin O’Reilly

Senior Director

+1-617-283-2285

Erin.Oreilly@BostonGene.com